These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34920925)

  • 21. Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment.
    Deng S; Lin Z; Li W
    Curr Med Chem; 2017; 24(23):2505-2527. PubMed ID: 28554322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New strategies for the management of triple-negative breast cancer.
    Riaz F
    Curr Opin Obstet Gynecol; 2024 Feb; 36(1):40-44. PubMed ID: 38170551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
    Campos MP; Konecny GE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design.
    Trail PA; Dubowchik GM; Lowinger TB
    Pharmacol Ther; 2018 Jan; 181():126-142. PubMed ID: 28757155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response.
    Bosi C; Bartha Á; Galbardi B; Notini G; Naldini MM; Licata L; Viale G; Mariani M; Pistilli B; Ali HR; André F; Piras M; Callari M; Barreca M; Locatelli A; Viganò L; Criscitiello C; Pusztai L; Curigliano G; Győrffy B; Dugo M; Bianchini G
    Eur J Cancer; 2023 Dec; 195():113379. PubMed ID: 37913680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarkers for Antibody-Drug Conjugates in Solid Tumors.
    Katrini J; Boldrini L; Santoro C; Valenza C; Trapani D; Curigliano G
    Mol Cancer Ther; 2024 Apr; 23(4):436-446. PubMed ID: 38363729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pathological and clinical landscape of refractory metastatic triple negative breast cancer: a narrative review.
    Jiang MP; Huang X; Yin YM; Tang JH
    Ann Transl Med; 2022 Aug; 10(16):907. PubMed ID: 36111045
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer.
    Leong SR; Liang WC; Wu Y; Crocker L; Cheng E; Sampath D; Ohri R; Raab H; Hass PE; Pham T; Firestein R; Li D; Schutten M; Stagg NJ; Ogasawara A; Koppada N; Roth L; Williams SP; Lee BC; Chalouni C; Peng I; DeVoss J; Tremayne J; Polakis P; Polson AG
    Mol Pharm; 2015 Jun; 12(6):1717-29. PubMed ID: 25853436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Top advances of the year: Breast cancer.
    Saavedra C; Gion M; Cortés J; Llombart-Cussac A
    Cancer; 2023 Jun; 129(12):1791-1794. PubMed ID: 37014257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances with antibody-drug conjugates in breast cancer treatment.
    Abdus Subhan M; Torchilin VP
    Eur J Pharm Biopharm; 2021 Dec; 169():241-255. PubMed ID: 34748933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new immunochemical strategy for triple-negative breast cancer therapy.
    Lin CW; Zheng T; Grande G; Nanna AR; Rader C; Lerner RA
    Sci Rep; 2021 Jul; 11(1):14875. PubMed ID: 34290315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer.
    Seligson JM; Patron AM; Berger MJ; Harvey RD; Seligson ND
    Ann Pharmacother; 2021 Jul; 55(7):921-931. PubMed ID: 33070624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benefits and challenges of antibody drug conjugates as novel form of chemotherapy.
    Fatima SW; Khare SK
    J Control Release; 2022 Jan; 341():555-565. PubMed ID: 34906604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triple-Negative Breast Cancer: Who Should Receive Neoadjuvant Chemotherapy?
    Chaudhary LN; Wilkinson KH; Kong A
    Surg Oncol Clin N Am; 2018 Jan; 27(1):141-153. PubMed ID: 29132557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advancements in the Treatment of Triple-Negative Breast Cancer: A Narrative Review of the Literature.
    Landry I; Sumbly V; Vest M
    Cureus; 2022 Feb; 14(2):e21970. PubMed ID: 35282535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer.
    Wali VB; Patwardhan GA; Pelekanou V; Karn T; Cao J; Ocana A; Yan Q; Nelson B; Hatzis C; Pusztai L
    Sci Rep; 2019 Oct; 9(1):14934. PubMed ID: 31624295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An intelligent cell-selective polymersome-DM1 nanotoxin toward triple negative breast cancer.
    Zhang Y; Yue S; Haag R; Sun H; Zhong Z
    J Control Release; 2021 Dec; 340():331-341. PubMed ID: 34774889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Future Developments in Neoadjuvant Therapy for Triple-Negative Breast Cancer.
    Moore-Smith L; Forero-Torres A; Stringer-Reasor E
    Surg Clin North Am; 2018 Aug; 98(4):773-785. PubMed ID: 30005773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.
    Jerjian TV; Glode AE; Thompson LA; O'Bryant CL
    Pharmacotherapy; 2016 Jan; 36(1):99-116. PubMed ID: 26799352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy.
    Nasiri H; Valedkarimi Z; Aghebati-Maleki L; Majidi J
    J Cell Physiol; 2018 Sep; 233(9):6441-6457. PubMed ID: 29319167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.